Amyris Achieves Promising In-Vivo Results For Intranasal Delivery Of RNA/NLC Vaccine
- Friday, August 20, 2021, 7:12
- Finance
- Add a comment
EMERYVILLE, Calif., Aug. 20, 2021 /PRNewswire/ — Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, today announced promising in-vivo…
About the Author
adminasapcorp has written 41834 stories on this site.